Form 4: Halozyme CEO Sells Shares, Gifts to Charity

Halozyme Therapeutics CEO Helen Torley reported a gift of 25,000 shares to charity and the exercise and immediate sale of 16,569 stock options.

Summary

• Helen Torley, President and CEO, and a Director of Halozyme Therapeutics, Inc. (HALO), reported changes in her beneficial ownership.
• On November 26, 2025, Torley made a bona fide gift of 25,000 shares of common stock to charity.
• On December 1, 2025, Torley exercised 16,569 options to purchase common stock at an exercise price of $8.11 per share.
• These options were granted on February 3, 2016, and were set to expire in February 2026.
• Immediately following the option exercise on December 1, 2025, Torley sold all 16,569 shares acquired from the exercise in multiple transactions.
• The sales occurred at weighted average prices ranging from $68.512 to $71.6 per share.
• All transactions on December 1, 2025, were executed under a Rule 10b5-1 trading plan adopted on March 21, 2025.
• Following all reported transactions, Torley's direct beneficial ownership of common stock is 708,719 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions, including a charitable gift and the exercise and sale of stock options under a pre-arranged 10b5-1 plan. These are standard activities for executives and do not inherently indicate a positive or negative sentiment about the company's future performance.

Positives

• The reporting person made a significant gift of 25,000 shares to charity, demonstrating philanthropic activity.
• The exercise of stock options indicates a personal gain for the executive, as the exercise price of $8.11 was significantly lower than the sale prices, reflecting the company's stock appreciation.

Negatives

• The sale of 16,569 shares by a key executive, even if pre-planned, could be perceived as a reduction in direct exposure to the company's stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The options exercised and sales reported were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025, in accordance with Rule 10b5-1.
• The sales of common shares reported represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

Industry Context

This Form 4 filing details routine insider transactions (option exercise, share sales, and a charitable gift) by a key executive. Such transactions are common in the biotechnology and pharmaceutical industry, particularly when executives exercise expiring stock options and manage their personal portfolios, often through pre-arranged 10b5-1 plans to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for the option exercise and subsequent sales aligns with best practices for corporate governance and insider trading compliance, common among executives in publicly traded companies, including those in the biotech sector.
• The exercise of options nearing their expiration date is a standard practice for executives to realize value from their equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions represent a minor change in the executive's direct ownership, with the sales being pre-planned and not necessarily indicative of a change in management's view of the company's prospects. The charitable gift reduces the executive's direct holdings.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Helen Torley, Insider Transaction, Form 4, Stock Options, Rule 10b5-1 Plan, Share Sale, Charitable Gift